Good performance in first half of 2015
|
|
- Martha Whitehead
- 5 years ago
- Views:
Transcription
1 co.don Aktiengesellschaft, Teltow H1 Interim Report 2015 Good performance in first half of 2015 Revenue up year on year by 18% Operating break even before strategic expenses for marketing approval Overall loss down significantly compared with last year Capital market profile boosted by new research coverage from two analysts Management handover advances internationalisation of business co.don AG continued its growth in the second half of 2015 and was able to develop its business successfully: The technology leader for autologous chondrocyte implants increased its revenue by 18% in the first half of 2015 and was able to turn around its operating business and break even before strategic expenses for EU marketing approval. The total loss was reduced significantly year on year, although the overall result was still depressed by high strategic expenses in connection with work to obtain EU marketing authorisation for the pharmaceutical product co.don condrosphere.
2 1. Overview of revenue REVENUE in Increase YOY ,085 Q , % ,064 Q , % Table 01a: Revenue for co.don AG by quarter REVENUE in Increase YOY ,149 H , % Table 01b: Revenue for co.don AG by half year Revenue was up by 18% in the first half of 2015 and the company was able to turn around its operating business and break even before strategic expenses for EU marketing approval. Page 2 of 11
3 EBIT in Increase YOY Q % Q % Table 02a: EBIT for co.don AG by quarter EBIT in Increase YOY ,167 H % Table 02b: EBIT for co.don AG by half year EBIT for co.don AG rose sharply to 784k in the first half year. (previous year period: 1,167k) Page 3 of 11
4 2. First half year 2015 Key figures The income statement (Table 3, page 6) for the period 1.1 to and the balance sheet with comparative figures as of were prepared in accordance with German commercial law (HGB). Total revenue for co.don AG increased again in the first half of 2015 compared with the same period last year to 2,539k (previous year period: 2,149k). For a better understanding of the course of business a supplementary table (Table 4, page 7) has been added to the income statement, in which operating and strategic expenses are shown separately. The cost of materials for raw materials, consumables and supplies and for purchased services came to 318k (previous year period: 299k). Staff expenses came to 1,558k in the first half of 2015 (previous year period: 1,419k). The increase was due to new recruitment. As of co.don AG had an average of 65 employees (previous year period: 61). Other operating expenses for the first half of 2015 amounted to 1,339k (previous year period: 1,494k). They particularly include strategic expenses for external services in connection with clinical trials and marketing approval, as well as sales and administrative expenses and various operating costs. The loss for the period of co.don AG for the first half of 2015 came to 786k (previous year period: 1,173k). Overall, the company's net income is still depressed by high strategic expenses in connection with work to obtain EU wide marketing authorisation for its pharmaceutical product co.don condrosphere. Adjusting the loss for the period for strategic expenses, however, means that operating earnings before interest, tax, depreciation and amortisation (EBITDA) were positive at 283k (previous year: 4k), which is a significant improvement. Cash and cash equivalents at co.don AG came to 1,735k as of The average monthly cash burn was 412k in the first half of 2015 (previous year period: 190k) as a result of extensive investment to fully modernise and expand the research laboratories. Shareholders' equity came to 3,501k as of As of equity amounted to 4,287k. Page 4 of 11
5 Share performance The codon share opened the year at a price of and climbed steeply from mid March 2015 onwards with strong trading volumes to a high of on This period saw the publication of the operating figures for 2014 on and the announcement of the Q1/2015 results on , which both underlined the company's positive performance. As in prior years, the Berlin Cartilage Symposium on generated additional reporting about co.don AG and so drew increasing attention to the share. Thereafter the share price declined again as new orders fell and is currently trading at around 2.70, which represents an increase of some 20% on the closing price for the year of 2.28 on In the same period the reference index All Biotech increased by approx. 21%, the DAX by approx. 12% and the General Standard Index by 5%. On average around 24,000 shares valued at approx. 61,000 were traded every day in the reporting period (Germany overall). Perception of the share on capital markets was boosted substantially by the inclusion of two research coverages. Both Sphene Capital GmbH, a research outfit based in Munich that specialises in the analysis of undervalued small caps, and Warburg Research GmbH from Hamburg recommended shares in co.don AG as a buy in their respective reports and announced a potential target price of 4.30 per share. Market potential We address a high volume range of indications for orthopaedic and accident surgery which has great long term promise. Experts put the market potential for articular preservation therapies in Germany alone at over 250 million and at over 1bn for the whole of Europe. The method of matrix associated autologous chondrocyte transplantation (M ACT) is firmly established in many German clinics. "Joint preservation before joint replacement" is the motto of more and more orthopaedic and accident surgeons to the benefit of their patients. We assume this trend applies throughout Europe. For this reason we are in the process of applying for EU marketing authorisation from the European Medicines Agency (EMA), so that with international approval we can gain access to the EU market and increase the value of co.don AG substantially, and in all likelihood sustainably too. International expansion into markets outside the EU offers further interesting and realistic prospects. Page 5 of 11
6 3. Income statement and balance sheet Table 3: Income statement as of in accordance with section 275 HGB (unaudited) condensed version Change in % Revenue 2,149 2, Other operating income Cost of materials Staff expenses 1,419 1, Depreciation and amortisation Other operating expenses 1,494 1, Other neutral expenses Interest and similar expenses 0 0 Result of operating activities 1, Other taxes Net income/loss for the period 1, Profit/loss carried forward 9,694 12, Transfer from capital reserve 0 0 Distributable profit/loss 10,867 12, Page 6 of 11
7 Table 4: Income statement as of , separating the operating business from strategic costs of authorisation (unaudited) Change in % Operating business Revenue 2,149 2, Other operating income 0 13 Cost of materials Staff expenses 1,016 1, Other operating expenses EBITDA ,975.0 Depreciation & amortisation EBIT Other neutral expenses 0 1 Neutral expenses Other taxes 6 0 Interest and similar expenses 0 2 Net income/loss for the period before strategic costs Strategic approval expenses Expenses for central marketing authorisation 1, Other operating income 0 15 Net income/loss for the period after strategic costs 1, Page 7 of 11
8 Table 5: Balance sheet as of in accordance with HGB (unaudited) condensed version Change in % Assets A. Non current assets I. Intangible assets II. Property, plant and equipment 879 1, B. Current assets I. Inventories (raw materials, consumables and supplies) II. Receivables and other assets III. Cash in hand, bank balances ,267 1, C. Prepaid expenses ,073 4, Equity and liabilities A. Shareholders' equity 4,287 3, I. Subscribed capital 13,722 13,722 II. Capital reserve 2,752 2,752 III. Distributable profit/loss 12,188 12, B. Provisions Other provisions 1, C. Liabilities ,073 4, Page 8 of 11
9 Opportunities and risks Recognising and exploiting opportunities for the benefit of co.don AG, but also identifying risks and limiting their effects, are the permanent responsibility of the Executive Board and all employees. The Executive Board sees risk management as a continuous process that forms part of the overall management of co.don AG. co.don AG has established a risk management system that is refined and adjusted on an ongoing basis. For a detailed description of opportunities and risks we refer to the annual report for 2014, item III of the management report, starting on page 31. The risks mentioned in 7 have decreased. "Risks from tax rulings". The risk that value added tax is deemed to apply retrospectively to foreign revenue has decreased substantially because the legal situation has changed since the financial year Since 2010 the principle has applied that other business to business services are subject to value added tax in the country where the customer is located. Even though we were not able to maintain our position that the revenue of co.don AG should be qualified as product deliveries, their classification as other services is not expected to result in sales being liable for VAT in Germany. We still believe there is a risk as far as input VAT is concerned. Now that the tax inspection for the years 2004 to 2006 is over this risk is limited to the financial years from 2009 onwards. Here it should be noted that parliament revised the regulations exempting certain companies from VAT as of As co.don AG generally has no personal relationship of trust to the patient, which could be used to justify an exemption from VAT, we also refer to the letter from the German Finance Ministry dated November This letter states that for tax exemption pursuant to section 4 no. 14b German VAT Act (UStG), not only must laboratory physicians be involved, but the institution must also qualify within the meaning of the statute. As co.don AG neither operates via laboratory physicians nor counts as a qualifying institution in our opinion, we do not see tax exemption pursuant to section 4 no. 14b UStG as being relevant. Given that the tax authorities did not view the matter any differently in the tax inspection for 2004 to 2006 and that we believe the risk of any conflicting ruling to be low in light of the current interpretation of the legal situation post 2009, we consider that this risk no longer jeopardises the company's existence, in contrast to prior years. Significant events in the reporting period The Supervisory Board appointed Dirk Hessel as an additional member of the Executive Board of co.don AG hat with effect from On he assumed overall responsibility as CEO and chairman of the Executive Board from Dr. Andreas Baltrusch, who is leaving the company after six successful years as CEO at his own request, in order to pursue other entrepreneurial activities. Page 9 of 11
10 Declaration by the legal representatives We declare that to the best of our knowledge and in accordance with the applicable accounting principles for interim reporting, the condensed interim financial statements give a true and fair view of the net assets, financial position and results of operations of the company and that the course of business, including the business result and the position of the company, are portrayed in such a way in the Management Report that a true and fair view is conveyed and that the main opportunities and risks of the company s expected future development are described. Teltow, Executive Board Dirk Hessel CEO Vilma Methner COO CSO Condensed notes to the interim financial statements These financial statements for the first half of 2015 were prepared in accordance with German commercial law (HGB). Unless stated otherwise, the same accounting principles were applied as for the commercial law financial statements for the financial year A detailed description of these accounting principles can be found in the annual report published for For comparison with the income statement for the period 1 January 2015 to 30 June 2015 we have provided the income statement for the period 1 January 2014 to 30 June The figures for the first half of 2014 have been taken from the unaudited interim financial statements. For comparison with the unaudited balance sheet for the first half year as of 30 June 2015 we have provided the audited balance sheet prepared in accordance with German commercial law as of 31 December The condensed financial statements as of 30 June 2015 and the interim management report have been neither audited nor reviewed by the auditors. Page 10 of 11
11 Contact co.don AG Matthias Meißner Telephone +49 (0) Investor Relations Fax +49 (0) Warthestraße 21 ir@codon.de D Teltow URL WKN A1K022 ISIN DE000A1K0227 Page 11 of 11
co.don AG Q1 substantially above last year 13 April 2015
13 April 2015 co.don AG Reuters: CNWK.DE Bloomberg: CNWK:GR Q1 substantially above last year Rating: Buy Price: EUR 2.88 Price target: EUR 4.20 Risk: Medium Q1/2015 at a glance In the first quarter 2015,
More informationIndustriestraße D Stuttgart Phone: Fax: Internet:
3-Months Report 2004 CENIT AG Systemhaus Industriestraße 52-54 D-70565 Stuttgart Phone: +49 711 7825-30 Fax: +49 711 7825-4000 Internet: http://www.cenit.de Investor Relations: Fabian Rau Phone: +49 711
More informationQuarterly Financial Report March 31, 2012 MBB Industries AG. Berlin
Quarterly Financial Report March 31, 2012 MBB Industries AG. Berlin MBB Industries in figures Page 1 MBB Industries in figures Three months 2011 2012 Δ 2012 / (unaudited) 2011 IFRS IFRS Earnings figures
More informationGERRY WEBER International AG Report on the first three months of 2007/2008. Report on the three-month period ended 31 January 2008
GERRY WEBER International AG Report on the first three months of 2007/2008 Report on the three-month period ended 31 January 2008 WKN: 330 410 ISIN: DE0003304101 The share In the first quarter of 2007/2008
More informationGERRY WEBER International AG Interim report Q2 2010/2011. Report on the six-month period ended 30 April 2011 WKN: ISIN: DE
GERRY WEBER International AG Interim report Q2 2010/2011 Report on the six-month period ended 30 April 2011 WKN: 330 410 ISIN: DE0003304101 The GERRY WEBER share Gaining roughly 27 percent, the GERRY WEBER
More informationDATAGROUP increases revenues and benefits from low interest rates
DATAGROUP increases revenues and benefits from low interest rates Q2 figures for FY 2015/2016 (01.01.-31.03.2016) Revenues up 4% to 41.1m (previous year 39.5m) Service share reaches 79% (previous year
More informationQuarterly Statements 1st to 3rd Quarter 2017
1st to 3rd Quarter 2017 Key figures Fair Value Group Revenues and earnings 1/1 30/9/2017 1/1 30/9/2016 Rental income in thousand 17,037 17,145 Net rental income in thousand 12,643 11,606 Operating result
More informationEarnings per share (basic) in EUR Earnings per share (diluted) in EUR Number of employees at end of period
At a glance January 1 until September, 30, 2018 in EUR k September 30, 2018 September 30, 2017 Sales 123,306 102,219 Gross profits 63,655 57,360 EBITDA 6,927 8,634 Operating returns (EBIT) 4,731 6,926
More informationDATAGROUP continues profitable growth
DATAGROUP continues profitable growth Q3 2016/2017 figures (01.04.-30.06.2017) Revenue 25% up yoy, EBITDA +103% EBITDA margin clearly double-digit at 13.0% Earnings per share jump to 45 cents Pliezhausen,
More informationfrancotyp-postalia holding ag Interim report III / 2010 franking inserting software solutions mail services our expertise for your mail
francotyp-postalia holding ag Interim report III / 2010 franking inserting software solutions mail services our expertise for your mail key figures to the 3rd quarter 2010 Figures in accordance with consolidated
More informationQuarterly Financial Report March 31, MBB Industries AG. Berlin
Quarterly Financial Report March 31, 2010 MBB Industries AG. Berlin Quarterly Financial Report March 31, 2010 MBB Industries AG MBB Industries in Numbers 03 MBB Industries in Numbers Three months (January
More informationQUARTERLY FINANCIAL REPORT MARCH 31, 2015
QUARTERLY FINANCIAL REPORT MARCH 31, 2015 MBB SE, Berlin MBB in figures Page 1 MBB in figures Three months 2015 2014 Δ 2015 / (unaudited) 2014 IFRS IFRS Earnings figures thou thou % Revenue 60,241 55,618
More informationINTERIM REPORT I/2012. mail CommunICatIon of the future
INTERIM REPORT I/2012 mail CommunICatIon of the future key figures for the 1st Quarter 2012 Figures in accordance with consolidated financial statements in EUR million 1.1. 31.3.2012 1.1. 31.3.2011 Changes
More informationInterim management statement
Interim management statement 1st to 3rd quarter of 2017 FIRST TO THIRD QUARTER AT A GLANCE DEUTZ Group: Overview 7 9/2017 7 9/2016 1 9/2017 1 9/2016 New orders 370.8 258.1 1,173.8 935.3 Unit sales (units)
More informationQuarterly Statement 1 st quarter 2018
Quarterly Statement 1 st quarter 2018 Selected figures (unaudited) Sales and result 01/01-03/31/2018 01/01-03/31/2017 Change Sales (KEUR) 2,782 3,095-10% EBITDA (KEUR) -1,588-1,665 +5% EBIT (KEUR) -1,998-2,151
More information2006 Quarterly Report I
2006 Quarterly Report I Ratios Quarterly Report I/2006 2 Q1 2006 Q1 2005 Change Revenue Million EUR 11.3 8.6 32% Return on revenue before tax % 9% 7 % 17% EBITDA Million EUR 2.2 1.6 40% EBIT Million EUR
More informationPHOENIX Pharmahandel GmbH & Co KG Pfingstweidstraße Mannheim Germany PHOENIX group
PHOENIX Pharmahandel GmbH & Co KG Pfingstweidstraße 10-12 68199 Mannheim Germany www.phoenixgroup.eu PHOENIX group WE GO FORWARD Half-year report February to July 2014 PHOENIX group We deliver health.
More informationDATAGROUP publishes preliminary FY 2015/2016 results
DATAGROUP publishes preliminary FY 2015/2016 results Strong increase in revenues of 11% EBITDA jumps 25% to 19.1m EBITDA margin of 10.9% in the double-digit range for the first time Pliezhausen, November
More informationCONSOLIDATED HALF-YEAR FINANCIAL REPORT
CONSOLIDATED HALF-YEAR FINANCIAL REPORT FOR THE FIRST HALF-YEAR 2018 1 FRANKFURT AM MAIN CONSOLIDATED HALF-YEAR IFRS FINANCIAL REPORT FOR THE PERIOD 1 JANUARY TO 30 JUNE 2018 TABLE OF KEY FIGURES 1.1.
More informationReport on the 2nd Quarter of 2005 Period under review January 1, 2004 till June 30, 2005
Report on the 2nd Quarter of 2005 Period under review January 1, 2004 till June 30, 2005 Regenerative Medicine Vorwort CONSOLIDATED GROUP curasan AG, D-Kleinostheim curasan Benelux BV, NL-Barneveld curasan
More informationQUARTE RLY RE PORT
QUARTE RLY RE PORT 1 2017 2018 Key Figures SinnerSchrader Group Q1 2017/2018 Q1 2016/2017 CHANGE Gross revenues 000s 14,365 13,269 +8 % Net revenues 000s 14,365 13,269 +8 % EBITDA 000s 467 1,491 69% EBITA
More informationH A L F - Y E A R L Y F I N A N C I A L R E P O R T 2018
VTG AG H A L F - Y E A R L Y F I N A N C I A L R E P O R T The VTG Group was able to maintain its positive start to the year in the second quarter of. The continuing positive economic climate gave rise
More information153.9EUR 19.6EUR 8.0EUR
Nine Months Report 2017 KENNZAHLEN KEY FIGURES DES ERSTEN QUARTALS 153.9EUR MILLION REVENUES 19.6EUR MILLION EBITDA 8.0EUR MILLION Free cash flow adjusted 2 FP IS AIMING AT 2020 TARGETS THE SUCCESS OF
More informationQUARTERLY- REPORT FEBRUARY OCTOBER
QUARTERLY- REPORT FEBRUARY OCTOBER 2018 CONTENT 2 THE FIRST NINE MONTHS AT A GLANCE 3 INTERIM GROUP MANAGEMENT REPORT 3 Business and economic environment 6 Risks and opportunities 6 Forecast 7 INTERIM
More informationReport on the nine-month period ended July 31, 2006 WKN: ISIN: DE
GERRY WEBER International AG Report on the first nine months of 2005/2006 Report on the nine-month period ended July 31, 2006 WKN: 330 410 ISIN: DE0003304101 The GERRY WEBER share An approximately 18 percent
More informationReport on the IIIrd Quarter of Period under review January 1, 2002 until September 30, Specialist for regenerative medicine
Report on the IIIrd Quarter of 2002 Period under review January 1, 2002 until September 30, 2002 Specialist for regenerative medicine CONSOLIDATED GROUP curasan AG, D-Kleinostheim curasan Benelux BV, NL-Barneveld
More informationInterim Statement for the 1 st Quarter 2016 of H&R AG
Interim Statement for the 1 st Quarter 2016 of H&R AG 2 H&R AG INTERIM STATEMENT FOR THE 1 ST QUARTER 2016 Overview Positive developments from previous quarters continue in Q1 2016 Strong demand leads
More informationquarterly financial report 30 September 2016
quarterly financial report 30 September 2016 Q3 2016 KEY FIGURES AT A GLANCE (IFRS) thousand from the income statement 30 September 2016 30 September 2015 Income from rents and leases 45,341 38,199 Net
More informationQUARTERLY REPORT I 2017
QUARTERLY REPORT I 2017 2 KEY DATA ECKERT & ZIEGLER 1 3/2017 1 3/2016 Change Sales million 37.6 35.8 + 5 % Return on revenue before tax % 15 11 + 32 % EBITDA million 7.7 6.3 + 21 % EBIT million 5.5 4.3
More informationConsolidated Statement of Comprehensive Income Consolidated Statement of Cash Flows Consolidated Statement of Shareholders Equity...
Group Management Report For The Three Months Ended March 31, 2009 Contents Group Management Report... 3 Overall Economy and Industry... 3 Revenue Development... 3 Earnings Development... 4 Research and
More information1st Quarterly Statement for the period from 01/10/2017 to 31/12/2017
1st Quarterly Statement for the period from 01/10/2017 to 31/12/2017 01/10/2017-01/10/2016 - Change Consolidated 31/12/2017 31/12/2016 Income Statement in T in T in % Revenue 29,535 22,180 33.2 Operating
More informationInterim Condensed Consolidated Financial Statements_ for the period 1 January to 31 March 2017
Interim Condensed Consolidated Financial Statements_ for the period 1 January to 31 March 2017 Consolidated Statements of Financial Position_ 2 Consolidated Statements of Financial Position_ Assets Notes
More informationCONSOLIDATED INTERIM FINANCIAL STATEMENTS
CONSOLIDATED INTERIM FINANCIAL STATEMENTS 30 JUNE 2018 2 UNAUDITED CONSOLIDATED STATEMENT OF PROFIT AND LOSS. 30 JUNE 2018 30 JUNE 2017 Revenue 257,231 126,707 Costs of sales 210,803 99,490 Gross profit
More informationSolid interim results in line with roadmap
PRESS RELEASE Paris, 13 September 2017 Solid interim results in line with roadmap Revenue up 4.9%, driven by strong growth internationally (+9.4%) Stable operating margin (EBITDA) at 13.5%, compared to
More informationQUARTERLY REPORT FEBRUARY TO APRIL
QUARTERLY REPORT FEBRUARY TO APRIL 2018 CONTENTS 2 THE FIRST QUARTER AT A GLANCE 3 INTERIM GROUP MANAGEMENT REPORT 3 Business and economic environment 6 Risks and opportunities 6 Forecast 7 INTERIM CONDENSED
More informationQuarterly Report I. MultiSource
2004 Quarterly Report I MultiSource Dear Shareholder, The first quarter of 2004 was marked by brisk acquisition activity, which brought four additional sales and revenue sources into the corporate group.
More informationReport on the IIIrd Quarter of 2005 Period under review January 1st, 2005 until September 30, 2005
Report on the IIIrd Quarter of 2005 Period under review January 1st, 2005 until September 30, 2005 Regenerative Medicine Vorwort CONSOLIDATED GROUP curasan AG, D-Kleinostheim curasan Benelux BV, NL-Barneveld
More informationINTERIM STATEMENT Q1 2018
INTERIM STATEMENT Q1 2018 DERMAPHARM AT A GLANCE Group results at a glance Q1 / 2018 Q1 / 2017 Revenue EUR million 137.5 118.1 Adjusted EBITDA* EUR million 36.2 28.9 Adjusted EBITDA margin* % 26.3 24.5
More information1ST INTERIM REPORT January March 2018
1ST INTERIM REPORT January March Adjusted EBIT improves slightly year on year to EUR 26m Network Airlines and Lufthansa Cargo with significant margin improvements Lufthansa German Airlines achieves its
More informationHalf-Yearly Report 2016
Half-Yearly Report 2016 Revenue expanded 5 % to EUR 38.3 million in first six months Orders on hand up 15 % to EUR 11.8 million Marked upturn in the second quarter report optimize! Half-yearly report 2016
More informationSolid 2017 results in line with targets
PRESS RELEASE Paris, 14 March 2018 Solid 2017 results in line with targets 5.0% revenue growth driven by the strong international momentum Continued active development strategy with over 3,150 beds added
More information2012QUARTERLY STATEMENT AS OF MARCH 31
2012QUARTERLY STATEMENT AS OF MARCH 31 To our Shareholders Tim Alexander Lüdke, Chief Executive Officer Dear shareholders, ladies and gentlemen, We had a solid start in the new year. In the first quarter
More informationInterim report as per March 31, 2017
Interim report as per March 31, 2017 Key financial figures Sales (in keur) Operating income (in keur) Financial income (in keur) 2013 7,978 2014 11,063 2015 13,659 2016 14,425 2017 14,795 3M 2017 14,795
More informationCOMMIT DELIVER AND I N T E R I M S T A T E M E N T AS AT 3 0 SEP TEM B ER
COMMIT AND DELIVER I N T E R I M S T A T E M E N T AS AT 3 0 SEP TEM B ER 2 0 1 8 Key Figures TOM TAILOR GROUP KEY FIGURES TOM TAILOR GROUP EUR million Revenue Q3 2017 Change relative Q1 Q1 Q3 2017 Change
More informationBayer AG successfully placed new shares at Euro per share
Ad-hoc-Report according to 15 WpHG Investor Relations 51368 Leverkusen www.investor.bayer.com Not for distribution in or into the United States of America, Australia, Canada, United Kingdom or Japan successfully
More informationQuarterly Financial Report September 30, 2012 MBB Industries AG. Berlin
Quarterly Financial Report September 30, 2012 MBB Industries AG. Berlin MBB Industries in figures Page 1 MBB Industries in figures Nine months 2011 2012 Δ 2012 / (unaudited) 2011 IFRS IFRS Earnings figures
More informationHalf-Year Interim Report report. optimize!
Half-Year Interim Report 2017 report optimize! Consolidated Key Figures Q2 2017 Q2 2016 Half-yearly report 2017 Half-yearly report 2016 Incoming orders (EUR million) 17.8 21.9 39.5 39.6 Revenue (EUR million)
More informationKSB Group. Half-year Financial Report 2018
KSB Group Half-year Financial Report 2018 CONTENTS 4 Interim Management Report 11 Interim Consolidated Financial Statements 12 Balance Sheet 13 Statement of Comprehensive Income 15 Statement of Cash Flows
More informationMOLOGEN AG: Interim Financial Statements as of March 31, 2010
MOLOGEN AG: Interim Financial Statements as of March 31, 2010 Content Foreword... Page 3 Interim management report for the period from January 1 to March 31, 2010... Page 5 Statement of financial position
More informationInterim financial statements as at 30 June 2016 (unaudited) and interim management report
Vontobel Financial Products GmbH, Frankfurt am Main Interim financial statements as at 30 June 2016 (unaudited) and interim management report Interim financial statements... 2 I. Balance sheet as at 30
More informationINTERIM REPORT 1 JULY - 30 SEPTEMBER 2018
INTERIM REPORT 1 JULY - 30 SEPTEMBER 2018 VICORE PHARMA HOLDING AB (PUBL) SUMMARY OF THE PERIOD The rights issue in September was oversubscribed by 33% and the company received SEK 82.4 million before
More informationKey figures of M1 Kliniken AG
INTERIM REPORT 2018 M1 Kliniken AG Key figures Key figures of M1 Kliniken AG Consolidated profit and loss statement according to IFRS (in ) 30.06.2018 30.06.2017 k Sales 28,926,972.60 22,257 EBT 4,276,814.69
More informationBUSINESS REPORT. for the first three months of the 2004 business year (unaudited)
BUSINESS REPORT for the first three months of the 2004 business year (unaudited) 2004 BUSINESS REPORT I/2004 SILICON SENSOR GROUP Financial ratios Jan. 01 2004 (first quarter 2004) 2004 TEuro 2003 TEuro
More informationIndustriestraße D Stuttgart Phone: Fax: Internet:
9-Months Report 2003 CENIT AG Systemhaus Industriestraße 52-54 D-70565 Stuttgart Phone: +49 711 7825-30 Fax: +49 711 7825-4000 Internet: http://www.cenit.de Investor Relations: Fabian Rau Phone: +49 711
More informationInterim Report January March 2017
Interim Report January March 2017 Significant events during the period 1 February Christer Ahlberg started as new CEO for Sedana Medical group. In March, AnaConDa was approved in South Korea, which is
More informationSTALLERGENES GREER DELIVERS 2018 SALES AND EBITDA IN LINE WITH RECENT OUTLOOK
STALLERGENES GREER DELIVERS 2018 SALES AND EBITDA IN LINE WITH RECENT OUTLOOK Net sales reached 277.0 million in reported currency, a 6% growth year-over-year (+8% in constant currency) EBITDA was 40.2
More informationQuarterly Financial Report
3/2015 Quarterly Financial Report Incoming orders at an all-time high of EUR 63.0 million Revenue up almost 8 % to EUR 57.3 million Guidance for the year confirmed Quarterly Financial Report 3/2015 Dear
More informationInterim Report. First half of 2017, BioPorto Group. August 10, 2017 Announcement no. 10. BioPorto A/S CVR DK
Interim Report First half of 2017, BioPorto Group August 10, 2017 Announcement no. 10 BioPorto A/S CVR DK-17500317 Highlights US Clinical study commencing according to announced plan BioPorto commenced
More informationHawesko Holding AG Hamburg ISIN DE Reuters HAWG.DE, Bloomberg HAW GR
Hawesko Holding AG Hamburg ISIN DE0006042708 Reuters HAWG.DE, Bloomberg HAW GR Quarterly financial report to 31 March 2014 Hamburg, 15 May 2014 Highlights in (millions) 2014 1st quarter 2013 +/ Consolidated
More informationQuarterly Financial Report. 1 January - 30 September 2017
Quarterly Financial Report 1 January - 30 September 2017 Quarterly Financial Report Table of contents Table of contents LPKF Laser & Electronics AG at a glance... 3 Spokesman's Statement... 4 Interim Management
More informationHalf-Year Interim Report report
Half-Year Interim Report 2018 report Consolidated Key Figures Q2 2018 Q2 2017 Half-yearly report 2018 Half-yearly report 2017 Incoming orders (EUR million) 23.3 17.8 44.4 39.5 Revenue (EUR million) 21.4
More informationQUARTERLY REPORT II 2016
QUARTERLY REPORT II 2016 2 KEY DATA ECKERT & ZIEGLER 1 6/2016 1 6/2015 Change Sales million 70.1 68.8 + 2 % Return on revenue before tax % 12 % 17 % 28 % EBITDA million 13.2 16.3 19 % EBIT million 9.2
More informationBEING THERE HALF-YEAR REPORT FEBRUARY TO JULY 2018
BEING THERE HALF-YEAR REPORT FEBRUARY TO JULY 2018 WE DELIVER HEALTH. EACH AND EVERY DAY. ACROSS EUROPE. The PHOENIX group is a leading pharmaceutical trader in Europe, reliably supplying people with drugs
More informationKEY FIGURES TOM TAILOR GROUP
#TTGRESET I N T E R I M S TAT E M E N T A S AT 31 M A R C H 2017 Key Figures TOM TAILOR GROUP KEY FIGURES TOM TAILOR GROUP EUR million Q1 2017 Q1 2016 Revenue 218.9 218.9 0.0% TOM TAILOR Retail 64.8 63.9
More informationPress release. Hypo Real Estate Group Corporate Communications Unsoeldstr Munich
Press release Hypo Real Estate Group preparing consolidated financial statements 2008 Unaudited consolidated pre-tax loss: 5.375 billion Special effects and one-off effects with considerable negative impact
More information9-Month Report of FJA AG
www.fja.com 9-Month Report of FJA AG 01.01.2008-30.09.2008 Contact FJA AG Elsenheimerstrasse 65 80687 Munich GERMANY Investor Relations Phone: + 49 89 76901-274 or -7002 Fax: + 49 89 7698813 Email: investor.relations@fja.com
More informationWe create value. TAG ı Interim report ı
We create value 27 1 TAG ı Interim report ı TAG Group in figures in TEUR 1/1/-3/31/7 1/1/-3/31/6 2 TAG ı TAG Group in figures ı Revenues 12,843 14,594 a) Sale of properties 3,72 8,83 b) Facility management
More informationCTS EVENTIM Aktiengesellschaft, Munich
CTS EVENTIM Aktiengesellschaft, Munich Nine-month Report 2001 Introduction Even in the third quarter of 2001 CTS EVENTIM AG expedited its strategic expansion of the company. The focus of attention can
More informationCELLINK AB (publ) Interim report September-November 2018/2019 (Q1)
CELLINK AB (publ) Interim report September-November 2018/2019 (Q1) 1 Interim report September-November 2018/2019 CELLINK AB (publ), org.nr. 559050-5052 Continued growth and improved margins. First quarter
More informationBEING THERE QUARTERLY REPORT FEBRUARY TO OCTOBER 2018
BEING THERE QUARTERLY REPORT FEBRUARY TO OCTOBER 2018 WE DELIVER HEALTH. EACH AND EVERY DAY. ACROSS EUROPE. The PHOENIX group is a leading pharmaceutical trader in Europe, reliably supplying people with
More informationInterim Report for the six months to 31st December Stock Code: ANCR. Veterinary Products for Companion Animals
Interim Report for the six months to Veterinary Products for Companion Animals Animalcare Group plc Interim Report Animalcare Group plc is focused on growing its veterinary business. Animalcare is a leading
More informationFast and sustainable, profitable growth. Company profile (February 2019)
Fast and sustainable, profitable growth. Company profile (February 219) Equity Story Highly profitable player with strong growth prospects on attractive real estate markets Sustainable, profitable business
More information9M QUARTERLY STATEMENT Financial Year
9M QUARTERLY STATEMENT 2017 Financial Year Key Figures of the MVV Energie Group 1 Euro million Sales and earnings 1 Oct 2016 to 30 Jun 2017 1 Oct 2015 to 30 Jun 2016 % change Sales excluding energy taxes
More informationInterim Group Management Report Consolidated Statement of Comprehensive Income Consolidated Cash Flow Statement... 8
Interim Group Management Report... 3 Consolidated Balance Sheet... 6 Consolidated Statement of Comprehensive Income... 7 Consolidated Cash Flow Statement... 8 Consolidated Statement of Changes in Equity...
More informationinterim report Q To our shareholders interim report GSW IMMOBILIEN AG Q MY BERLIN. MY HOME.
GsW interim report Q1-2013 To our shareholders interim report GSW IMMOBILIEN AG Q1-2013 MY BERLIN. MY HOME. Highlights Operational Highlights 31.03.2013 31.03.2012 Vacancy rate (residential) 2.7 % 3.3
More informationQuarterly Report January to September Years. With experience into future
Quarterly Report January to September 2017 Years With experience into future Key Stock Figures 9M 2017 Letter to the Shareholders Ticker symbol / Reuters symbol V3V / V3VGn.DE Securities number / ISIN
More informationQUARTERLY REPORT II 2018
QUARTERLY REPORT II 2018 2 KEY DATA ECKERT & ZIEGLER 1 6/2018 1 6/2017* Change Sales million 81.0 64.8 + 25 % Return on revenue before tax % 15 15 0 % EBITDA million 17.0 14.4 + 18 % EBIT million 12.8
More information6-Month Report Investor Relations: Tel Fax:
CENIT AG Industriestraße 52-54 70565 Stuttgart Tel. +49 7 11 78 25-30 Fax: +49 7 11 78 25-40 00 ISIN: DE0005407100 Internet: www.cenit.de Investor Relations: Tel. +49 7 11 78 25-3320 Fax: +49 7 11 78 25
More informationQuarterly Report 01/04
1 First Quarter Revenues on Last Year s Very Good Level Quarterly Report 01/04 January - March At 65.1 Million, EBIT Down 2.7 Million At 54.9 Million Earnings After Taxes Up Slightly Year-on-Year Despite
More informationFinancial report as at 30 June Condensed Group Management Report of Einhell Germany AG. Overview of January - June 2017
P I D I O N N W R W R R F C L R Ü R V K C T A A S H L R A N T G L A T K U. K U N D G A R T N. Dear shareholder, The financial report of the inhell Group as at 30 June 2017 meets the requirements under
More informationInterim Results 6-month figures FY 11
Interim Results 6-month figures FY 11 Bernhard Schreier, CEO Dirk Kaliebe, CFO Andreas Trösch, Head of Investor Relations Heidelberger Druckmaschinen AG November 10, 2010 Highlights Q2 FY 11 650 million
More informationUnaudited condensed consolidated interim financial statements for the first half-year 2018
Unaudited condensed consolidated interim financial statements for the first half-year 2018 Eurogrid GmbH Berlin Page 1 of 17 Consolidated income statement 1 Jan to 30 June 2018 1 Jan to 30 June 2017 (restated*)
More informationThe Art of Shopping. Interim Report H1 2005
The Art of Shopping Interim Report H1 2005 Key Figures Key Group Figures 1 Jan.- 1 Jan.- E million 30 June 2005 30 June 2004 Change Revenue 35.2 30.7 14% EBIT 28.4 24.3 17% Net finance costs -13.9-12.2-14%
More informationFIRST QUARTER UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, «
FIRST QUARTER UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2018 20 «18 Group key figures at a glance SELECTED GROUP KEY FIGURES Q1 2018 Q1 2017 Change Percent Consolidated sales 8,996
More informationGeratherm Medical AG Half-yearly report Jan.-June 2010
Geratherm Medical AG Half-yearly report 2010 2 GERATHERM AT A GLANCE Group financial ratio Jan.-June 2010 Jan.-June 2009 Change Turnover 7,997 keur 6,345 keur 26.0% Including export share 6,946 keur 5,086
More informationCARING FOR PEOPLE QUARTERLY REPORT FEBRUARY TO APRIL
CARING FOR PEOPLE QUARTERLY REPORT FEBRUARY TO APRIL 2017 We deliver health. Each and every day. Across Europe. > The PHOENIX group is a leading pharmaceutical trader in Europe, reliably supplying people
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
News Release Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-1 www.news.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer
More information3RD INTERIM REPORT January September 2018
3RD INTERIM REPORT January September Adjusted EBIT of EUR 2,362m slightly below record in the previous year, mainly due to one-off integration expenses at Eurowings Network Airlines fully compensate for
More informationThe Art of Shopping. Interim Report Q1 2005
The Art of Shopping Interim Report Q1 2005 Key Figures Key Group Figures 1 Jan. 1 Jan. E million 31 Mar. 2005 31 Mar. 2004 Change Revenue 17.4 14.9 17% EBIT 13.8 13.2 5% Net finance costs -6.8-5.0-36%
More informationInterim Report January March 2016
Q1 Interim Report January March 2016 Published on April 28, 2016 WACKER is one of the world s largest producers of hyperpure polycrystalline silicon, which is the key raw material for solar cells and semiconductors.
More informationINTERIM REPORT JANUARY - JUNE 2011
INTERIM REPORT JANUARY - JUNE INTERIM GROUP MANAGEMENT REPORT RIB SOFTWARE AG INTERIM GROUP MANAGEMENT REPORT A. BUSINESS AND GENERAL ENVIRONMENT Development of the world economy and effects on IT investments
More informationInterim Report as at 30 September 2007
Interim Report as at 30 September 2007 Viscom AG Contents Contents Interim Report as at 30 September 2007 Key Group Figures... 3 Foreword by the Executive Board... 4 Viscom s Shares... 6 Consolidated Interim
More informationINTERIM REPORT ON THE... Three Quarters
INTERIM REPORT ON THE... Three Quarters of 2005 1 Key Figures... Q3 2005 Q3 2004 9M 2005 9M 2004 3 months 3 months 9 months 9 months EUR thousand if not otherwise indicated (unaudited) (unaudited) (unaudited)
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Innovation is our future 2015 was a very successful
More informationBachem. Leading beyond peptides
Bachem. Leading beyond peptides Half-Year Report 2007 Half-Year Report 2007 New record results for Bachem in the first half of 2007 Sales growth of 25.4% in CHF and 26.3% in local currencies APIs and new
More informationJan.-March Result per share pursuant to DVFA* 0.18 EUR 0.02 EUR >100.0 %
Geratherm Medical AG Interim Report 1 st Quarter of 2010 2 GERATHERM AT A GLANCE Group financial ratio Jan.-March 2009 Jan.-March 2008 Change Turnover 3,958 3,113 27.2 % Including export share 3,417 2,386
More informationInterim report as per September 30, 2018
Interim report as per September 30, 2018 Key financial figures Sales (in keur) Operating income (in keur) Financial income (in keur) 2014 34,345 2015 41,863 2016 47,199 2017 45,373 2018 48,062 9M 2018
More informationfeelestate.de Key Group Data Key Share Data Dear Shareholders, Dear Readers, 3 million million, up from million in 2007.
Key Group Data Letter from the Executive Board 2007 2008 3 million 01.01.-30.06. 2008 01.01.-30.06. 2007 Change Revenue 55.2 45.6 21% EBIT 46.0 37.8 22% Net finance costs -24.1-19.7-22% EBT 26.3 18.2 45%
More information9-month report 2017 / 2018
9-month report 2017/2018 Key share data 9M 2017 / 2018 Ticker / ISIN K1R / DE000AOKFUJ5 Number of shares 4,124,900 Closing price (31/3/2018)* EUR 12.20 High / low* EUR 15.00 / EUR 11.70 Market capitalisation
More informationNordzucker AG Interim Report- Financial Year 2011/2012
Nordzucker AG Interim Report- Financial Year 2011/2012 First Half-Year March 1 August 31, 2011 Nordzucker Half-Year Report 2011/2012 Group figures and ratios 2 Group figures and ratios first half-year
More information